Thiogenesis Therapeutics, Corp. (TSXV:TTI)
Canada · Delayed Price · Currency is CAD 0.8200
+0.0300 (3.80%)
Jul 22, 2025, 4:00 PM EDT
Thiogenesis Therapeutics Company Description
Thiogenesis Therapeutics, Corp., a clinical-stage biopharmaceutical company, develops thiol-based therapeutic compounds to treat unmet pediatric medical needs.
Its lead product candidate is TTI-0102, a prodrug that consists of cysteamine for use in the treatment of mitochondrial encephalopathy lactic acidosis and stroke-like episodes, leigh syndrome, pediatric metabolic dysfunction-associated steatohepatitis, and rett syndrome.
The company is headquartered in Toronto, Canada.
Thiogenesis Therapeutics, Corp.
| Country | Canada |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Patrice Rioux |
Contact Details
Address: 4 King Street West Toronto, Ontario M5H 1B6 Canada | |
| Phone | 888-223-9165 |
| Website | thiogenesis.com |
Stock Details
| Ticker Symbol | TTI |
| Exchange | TSX Venture Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CAD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Patrice P. Rioux M.D., Ph.D. | Co-Founder, Chief Executive Officer and Director |
| Brook G. Riggins C.F.A. | Chief Financial Officer, Secretary and Director |
| Mary Jo Bagger | Consultant for Clinical Operations |